GWPH Snapshot
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Market Capitalization$6,683,618,304
Price to Sales12.72
Earnings per Share$1.0650
PE Ratio91.1417
Most Recent Close$214.8900
52 Week High$216.9
52 Week Low$67.98
50-Day Moving Average$178.7767
200-Day Moving Average$126.5001
All data are from Alpha Vantage as of today. For more infomation on GWPH see Stock Dividend, Valuation, Price and Financial Data for Investors